541 SEROLOGIC AND VIROLOGIC KINETICS AFTER STOPPING NUCLEOSIDE ANALOGUE THERAPY IN HEPATITIS B SURFACE ANTIGEN (HBSAG) SEROCLEARANCE

539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS T. Piratvisuth, P. Komolmit, T. Tanwandee, W. Sukeepaisarnjaroen, H.L. Chan, M.G. Pessoa, E. Fassio, S. Ono-Nita, F. Bessone, J. Daruich, S. Zeuzem, H. Cheinquer, Y. Dong, A. Trylesinski. NKC Institute of Gastroenterology and Hepatology Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Department of Medicine Gastroenterology Unit, Chulalongkorn University Hospital, Siriraj Hospital, Bangkok, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; The Chinese University of Hong Kong, Hong Kong, Hong Kong S.A.R.; Hospital das Clinicas da Faculdade de Medicina da USP, Sao Paolo, Brazil; Hospital Nacional Prof. Alejandro Posadas, Buenos Aires, Argentina; Departamento de Gastroenterologia da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil; Catedra de Cĺinica Medica, Universidad Nacional de Rosario, Rosario, Antigua & Barbuda, Hospital de Cĺinicas San Martin, University of Buenos Aires, Buenos Aires, Argentina; Klinikum der Johann-Wolfgang-Goethe-Universitaet, Frankfurt am Main, Germany; Hospital de Cĺinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil; Novartis Pharma, AG, Basel, Switzerland E-mail: teerha.p@psu.ac.th